Skip to Main Content

Paper Details

Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.
Blood Adv
3
2021
B, B-cell, B-cell lymphoma, BCL6, BL, Burkitt lymphoma, FBXO11, FBXO11 gene, FBXO11 mutations, FBXO11 protein, MYC, Omomyc mini-protein, human, human BL cell lines, lymphoma, mice, mouse, oncogenic MYC, patients, promoter regulatory regions, tumors, ubiquitin, wild-type and FBXO11-deficient BL mouse and human cell lines
Author NameAffiliation
Bruno M Grande
Ryan D MorinSimon Fraser University
Louis M StaudtCenter for Cancer Research and Biometric Research Program, National Cancer Institute, National Institutes of Health
Louis M StaudtCenter for Cancer Research and Biometric Research Program, National Cancer Institute, National Institutes of Health
Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm University Medical Center
  • 1 - 5

Datasets

Release 1.2